Renal transplantation, immunosuppression and the skin: An update

Photodermatology Photoimmunology and Photomedicine

Volumn 21, Issue 1, 2005, Pages 1-8

  Moloney, Fergal J ^a   de Freitas, D ^a   Conlon, P J ^a   Murphy, G M ^a  

^a BEAUMONT HOSPITAL   (Ireland)

Author keywords

Drug interactions; Immunosuppression; Renal transplantation; Skin cancer

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN; CALCINEURIN INHIBITOR; CLARITHROMYCIN; CLOTRIMAZOLE; CORTICOSTEROID; CYCLOSPORIN A; CYTOCHROME P450; DACLIZUMAB; DAPSONE; ERYTHROMYCIN; EVEROLIMUS; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN; MICONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; POLYCLONAL ANTIBODY; RAPAMYCIN; RIFAMPICIN; RNA; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ACNE; ALOPECIA; ANGIONEUROTIC EDEMA; APHTHOUS STOMATITIS; ARTHRALGIA; AWARENESS; BONE MARROW SUPPRESSION; CANCER RISK; CANDIDIASIS; CATARACT; CLINICAL PROTOCOL; CLINICAL TRIAL; DIABETES MELLITUS; DIAPHORESIS; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECCHYMOSIS; EVIDENCE BASED MEDICINE; EYELID EDEMA; FLUSHING; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GOUT; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERTROPHY; HYPOKALEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; KIDNEY TRANSPLANTATION; LONG TERM CARE; LUNG TOXICITY; LYMPHEDEMA; MAINTENANCE THERAPY; MEDICAL SPECIALIST; MOLECULAR MECHANICS; MOUTH ULCER; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; PANCREATITIS; PERIPHERAL EDEMA; PHOTOSENSITIVITY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PRURITUS; PURPURA; RASH; REVIEW; RISK BENEFIT ANALYSIS; SEBACEOUS GLAND DISEASE; SKIN BURNING SENSATION; SKIN CANCER; SKIN DISEASE; STEVENS JOHNSON SYNDROME; STRIA; TELANGIECTASIA; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; ULTRAVIOLET RADIATION; WHOLE BODY RADIATION; WOUND HEALING IMPAIRMENT;

DERMATOLOGIC AGENTS; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SKIN DISEASES; SKIN NEOPLASMS;

EID: 13444274870     PISSN: 09054383     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2005.00128.x     Document Type: Review

References (54)

1. Lindelof B, Sigurgeirsson B, Gabel H, Stern RS. Incidence of skin cancer in 5636 patients following organ transplantation. Br J Dermatol 2000; 143: 513-519.
2. Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Factors associated with nonmelanoma skin cancer following renal transplantation in Queensland, Australia. J Am Acad Dermatol 2003; 49: 397-406.
3. Giampieri S, Storey A. Repair of UV-induced thymine dimers is compromised in cells expressing the E6 protein from human papillomaviruses types 5 and 18. Br J Cancer 2004; 90: 2203-2209.
4. Oplez G, Michey MR, Terasaki PI. HLA matching and cadaver kidney transplant survival in North America: influence of center variation and presensitization. Transplantation 1977; 23: 490-497.
5. Merion RM, White DJ, Thiru S, Evans DB, CAlne RY. Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med 1984; 310: 148-154.
6. Calne RY. Cyclosporin in cadaveric renal transplantation: 5-year follow-up of a multicentre trial. Lancet 1987; 2: 506-507.
7. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983.
8. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029-1037.
9. Keown P, Niese D. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Kidney Int 1998 Sep; 54: 938-944.
10. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782.
11. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436-443.
12. Bunnapradist S, Daswani A, Takemoto SK. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids. Transplantation 2003; 76: 10-15.
13. Thervet E, Pfeffer P, Scolari MP, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76: 903-908.
14. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group. Transplantation 1999; 68: 391-396.
15. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405-2409.
16. Machado PG, Felipe CR, Hanzawa NM, et al. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination. Clin Transplant 2004; 18: 28-38.
17. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
18. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355: 376-377.
19. Ciancio G, Burke GW, Suzart K, et al. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002; 73: 1100-1106.
20. Ponticelli C, Yussim A, Cambi V, et al. Simulect Phase IV Study Group A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients. Transplantation 2001; 72: 1261-1267.
21. Otley CC, Coldiron BM, Stasko T, Goldman GD. Decreased skin cancer after cessation of therapy with transplant-associated immunosuppressants. Arch Dermatol 2001; 137: 459-463.
22. Moloney FJ, Kelly PO, Kay EW, Conlon P, Murphy GM. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg 2004; 30 (Part 2): 674-678.
23. Stallone G, Di Paolo S, Schena A, et al. Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients. Transplantation 2003; 75: 998-1003.
24. Oberbauer R, Kreis H, Cyclosporine Withdrawal Study Group. et al. Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study. Transplantation 2003; 76: 364-370.
25. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74: 1725-1734.
26. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076.
27. Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917.
28. Ahsan N, Hricik D, Matas A, et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil - a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865-1874.
29. Matas AJ, Ramcharan T, Paraskevas S, et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001; 1: 278-283.
30. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306-311.
31. Shuttleworth D, Marks R, Griffin PJA, Salaman JR. Epidermal dysplasia cyclosporine therapy in renal transplant patients: a comparison with azathioprine. Br J Dermatol 1989; 120: 551-554.
32. Mouquet C, Benalia H, Ourahma S, et al. Incidence of noncutaneous malignancies in kidney transplant recipients: a 20-year follow-up. Transplant Proc 1995; 27: 1764.
33. Hiesse C, Larue JR, Kriaa P, et al. Incidence and type of malignancies occurring after renal transplantation in conventionally and in cyclosporine-treated recipients: single-center analysis of a 20-year period in 1600 patients. Transplant Proc 1995; 27: 2450-2451.
34. Zuniga AV, Alvarez AL, Diliz PH. Neoplasia in renal transplantation. Transplant Proc 1996; 28: 3332.
35. Behrend M, Kolditz M, Kliem V, et al. Malignancies in patients under long-term immunosuppression after kidney transplantation. Transplant Proc 1997; 29: 834-835.
36. Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period. Transplant Proc 1997; 29: 831-833.
37. Glover MT, Deeks JJ, Raftery MJ, Cunningham J, Leigh IM. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997; 349: 398.
38. Penn I. Cancers following cyclosporine therapy. Transplantation 1987; 43: 32-35.
39. Barr BBB, McLaren K, Smith IW, et al. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1989; 1: 124-129.
40. Blohme I, Larkoe O. Skin lesions in renal transplant patients after 10-23 years of immunosuppressive therapy. Acta Derm Venereol (Stockh) 1990; 70 (Suppl.): 491-494.
41. Espana A, Redondo P, Fernandez AL, et al. Skin cancer in heart transplant recipients. J Am Acad Dermatol 1995; 32: 458-465.
42. Marks R, Kolley D, Lectas S. The risk of childhood exposure to sunlight in the development of solar keratoses and nonmelanotic skin cancer. Med J Aust 1990; 152: 62-66.
43. Bunney MH, Benton EC, Barr BB, Smith IW, Anderton JL, Hunter JA. The prevalence of skin disorders in renal allograft recipients receiving cyclosporin A compared with those receiving azathioprine. Nephrol Dial Transplant 1990; 5: 379-382.
44. Gruber SA, Skjei KL, Sothern RB, et al. Cancer development in renal allograft recipients treated with conventional and cyclosporine immunosuppression. Transplant Proc 1991; 23: 1104-1105.
45. Blohme I, Larkoe O. No difference in skin cancer incidence with or without cyclosporine - a five-year perspective. Transplant Proc 1992; 24: 313.
46. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia: a follow up study. Transplantation 1996; 61: 715-721.
47. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530-534.
48. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-betal expression and promotes tumor progression. Transplantation 2003; 76: 597-602.
49. Jonas S, Rayes N, Neumann U, et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 1141-1150.
50. Frezza EE, Fung JJ, van Thiel DH. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 1997; 44: 1172-1181.
51. Euvrard S, Ulrich C, Lefrancois N. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 2004; 30 (Part 2): 628-633.
52. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18: 446-449.
53. Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245-254.
54. Arceci RJ, Stieglitz K, Bierer BE. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype. Blood 1992; 80: 1528-1536.